Skip to main content
. Author manuscript; available in PMC: 2012 Jul 23.
Published in final edited form as: Cochrane Database Syst Rev. 2011 Jul 6;(7):CD008305. doi: 10.1002/14651858.CD008305.pub2

Appendix 12. Adverse events (1) part 2.

Characteris-
tic		 Jing A, 2009 Li KL, 2006 Li LH, 2005 Liu L, 2000 Lu GP, 1998 Ma YL, 2002 Qi MY, 2004
Interven-
tion(s) & con-
trol(s)		 I: DMC C: pravastatin I: Xuezhikang
C: simvastatin		 I: Xuezhikang
C1 :Zocer
C2: Mevalotin		 I: Xuezhikang
C: inositol
nicotinate		 I: Xuezhikang
C: simvastatin		 I: Xuezhikang
C: Marine
Triglycerids		 I: Xuezhikang
C: simvastatin
Deceased par-
ticipants [n]		 I: 0
C: 0
Total: 0		 I: 0
C: 0
Total: 0 :		 I: 0
C1 : 0
C2: 0
Total: 0		 I: 0
C: 0
Total: 0		 I: 0
C: 0
Total: 0		 I: 0
C: 0
Total: 0		 I: 0
C: 0
Total: 0
Adverse events
[n / %]		 I: 26.7%(8/
30)
C: 6.7%(2/
30) Total: 16.7%
(10/60)		 I: 10%(4/40)
C: 22.5%(9/
40)
Total: 16.25%
(13/80)		 I: 0 C1: 5%(1/20)
C2: 5%(1/20)
Total: 3.3%
(2/60)		 I: 11.7%(7/
60)
C: 27.6%(16/
58) Total: 19.5%
(23/118)		 I: ./.
C: ./.
Total: ./.		 I: 0
C: 0
Total: 0		 I: 16.1%(18/
112)
C: 18.8%(21/
112)
Total: 17.4%
(39/224)
Serious ad-
verse events [n
/%]		 I: 0
C: 0
Total: 0		 I: 0
C: 0
Total: 0		 I: 0
C1: 0
C2: 0
Total: 0		 I: 0
C: 0
Total: 0		 I: ./.
C: ./.
Total: ./.		 I: 0
C: 0
Total: 0		 I: 0
C: 0
Total: 0
Drop-outs
due to adverse
events [n / %]		 I: 0
C: 0
Total: 0		 I: 0
C: 0
Total: 0		 I: 0
C1: 0
C2: 0
Total: 0		 I: 0
C0
Total: 0		 I: ./.
C: ./.
Total: ./.		 I: 0
C: 0
Total: 0		 I: 0
C: 0
Total: 0
Hospitalisa-
tion [n / %]		 I: ./.
C: ./.
Total: ./.		 I: ./.
C: ./.
Total: ./.		 I: ./.
C1: ./. C2: ./.
Total: ./.		 I: ./.
C: ./.
Total: ./.		 I: 0
C0
Total: 0		 I: ./.
C: ./.
Total: ./.		 I: ./.
C: ./.
Total: ./.
Out-patient
treatment [n /
%]		 I: ./.
C: ./.
Total: ./.		 I: ./.
C: ./.
Total: ./.		 I: ./.
C1: ./.
C2: ./.
Total: ./.		 I: ./.
C: ./.
Total: ./.		 I: 100%
C: 100%
Total: 100%		 I: ./.
C: ./.
Total: ./.		 I: ./.
C: ./.
Total: ./.
Symptoms [n
/%]		 I: Diarrhea (8
cases)
C: myalgia(1
case), epigas-
tric discom-
fort(1 case)
Total: Di-
arrhea (80%),
myalgia
(10%), epigas-
tric discom-
fort(10%)		 I: increased ALT
(2 cases), ab-
dom-
inal distention
(2 cases)
C:
increased ALT
(3 cases), ab-
dominal dis-
ten-
tion(4 cases),
dry mouth(2
cases) Total: in-
creased ALT(5
cases, 38.5%),
abdominal
distention(6
cases, 46.2%)
, dry mouth(2
cases, 15.3%)		 I: NO
C1: CPK in-
creased(1 case)
C2: ALT in-
creased(1 case)
Total: CPK in-
creased(50%),
ALT increased
(50%)		 I: upset stom-
ach and diar-
rhea (2 cases),
muscular pain
( 3 cases), in-
creased SGPT
(4 cases)
C: upset stom-
ach and belch-
ing (9 cases), in-
creased SGPT
(6 cases)
, erubescence
and pruritus(8
cases)
Total: upset stomach
and diar-
rhea (2 cases),
muscular pain
( 3 cases), in-
creased SGPT
(10cases) up-
set stom-
ach and belch-
ing(9 cases)
, erubescence
and pruritus(8
cases)		 I: ./.
C: ./.
Total: ./.		 I: NO
CNO
Total: NO		 I: gastroin-
testinal symp-
toms
(14 cases), in-
creased ALT(4
cases) C: gastroin-
testinal symp-
toms(16 cases)
, increased
ALT(5 cases)
Total: gastrointesti-
nal symptoms
(30 cases), in-
creased ALT(
9 cases)

Footnotes

./.: not reported

C: control; I: intervention; NO: not observed